New production capacity strengthens MPM Medical’s position as a leading U.S. manufacturer and follows the company’s recent launch of collagen at-home wound care kits
IRVINE, Calif., Dec. 16, 2025 /PRNewswire/ — OrthAlign, Inc., a global leader in surgical navigation technologies, today announced the expansion of its Lantern® Hip platform to include support for posterior-based approaches in total hip arthroplasty (THA).
P&F USA, Inc., the U.S. subsidiary of heart valve manufacturer P&F Products and Features GmbH, today announced that the U.S. Food and Drug Administration (FDA) has approved initiation of the TRICAV II Pivotal Trial.
NES ZIONA, Israel, Dec. 8, 2025 /PRNewswire/ — EyeYon Medical Ltd., a global leader in ophthalmic innovation, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to initiate a U.S. clinical study of EndoArt®, the world’s first synthetic endothelial layer for the treatment of chronic corneal edema. EndoArt® is currently designated by the FDA as a Breakthrough Device.
SS Innovations (Nasdaq:SSII) announced today that it submitted a 510(k) premarket notification to the FDA for its Mantra surgical robot.
Commercialisation efforts for mjn-neuro’s EPISERA sensor in Europe will be handled by Neuraxpharma.
Microbot is collaborating with Emory to establish an Endovascular Robotics Program in interventional radiology to enhance the growing and evolving specialty field.
RESTON, Va., Nov. 25, 2025 /PRNewswire/ — VSI® Spine Surgeon Dr. Christopher Good has achieved a historic milestone in robotic spine surgery, performing the world’s first minimally invasive robotic Bertolotti’s resection surgery at Reston Hospital Center (HCA Virginia Health System). This first-ever procedure introduces a transformative surgical option for patients suffering from chronic low back pain caused by Bertolotti syndrome, an underdiagnosed spinal condition affecting an estimated 4-8% of the population.
PARAMUS, N.J., Nov. 25, 2025 /PRNewswire/ — Regenity Biosciences, a global leader in regenerative medicine and Linden Capital Partners portfolio company, today announced its 63rd FDA 510(k) clearance for DuraMatrix® Repair – Collagen Dura Regeneration Membrane, a resorbable membrane composed of highly purified Type I and Type III bovine collagen for the repair of dura mater defects during neurosurgery.
Recor Medical said today that it secured Medicare approval, granting coverage for the company’s RADIANCE CED study.